People · Operator
Named in public records as an officer, director or promoter · active 2017–2023 · Biotech / Pharma, Other Technology, Healthtech, Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Akoya Biosciences, Inc. | — | Biotech / Pharma | Series B | $33.5M | $901.1M | 2017 |
| Invisalert Solutions, Inc. | — | Other Technology | Series A | $14.7M | $52.0M | 2019 |
| GrayHawk Health, Inc. | — | Healthtech | Series A | $13.3M | $103.1M | 2023 |
| Nimble Therapeutics, Inc. | — | Biotechnology | Series A | $10.0M | $361.5M | 2019 |
| Aquaro Histology, Inc. | — | Biotechnology | Series A | $9.8M | $354.7M | 2017 |
Rob Hart at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Rob Hart on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| DEVAL LASHKARI | 2 | 6 |
| Thomas Raffin | 2 | 4 |
| Jack Ball | 1 | 10 |
| Robert Shepler | 1 | 4 |
| Matthew Winkler | 1 | 3 |
| Mark Gold | 1 | 3 |
| Gary Curtis | 1 | 2 |
| Garry Nolan | 1 | 2 |
| Pete Nagy | 1 | 2 |
| Marc Watkins | 1 | 2 |
| Jigar Patel | 1 | 2 |
| Alberto Elli | 1 | 1 |
| Raymond Falci | 1 | 1 |
| Andrew Henderson II | 1 | 1 |
| Tom Raffin | 1 | 1 |
| Brian McKelligon | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.